If you've been on LinkedIn or following AI news this week, you've probably seen the firestorm.
Matt Shumer, CEO of HyperWrite, published an extensive essay called "Something Big Is Happening" that has now been viewed over 55 million times. His thesis: AI has crossed a threshold, most white-collar jobs are at risk within one to five years, and if you're not aggressively adapting right now, you're sleepwalking into irrelevance. He compared this moment to February 2020 — that brief window before COVID upended everything — and warned that the people who dismiss the warning signs will be the ones caught unprepared.
Then Ann Handley, a widely respected voice in content marketing, fired back with a sharp, thoughtful counterpoint. She didn't dismiss AI. She dismissed the panic. Her argument: Shumer's framing reduces all work to a speed competition, and in doing so, erases the value of judgment, relationships, and the kind of deep expertise that only accumulates through years of doing the hard work. Her line that stayed with me: “When speed becomes cheap, judgment carries a premium.”
Here's what I keep coming back to: they're both right but in our highly regulated industry, there's more to it.
Where Matt Raises Legitimate Concerns
Let me be direct: I'm more aligned with Matt's sense of urgency than not.
I've spent 20+ years in health technology and clinical research. I was involved in the launch of the world's first eConsent platform, I navigated acquisitions from SecureConsent to DrugDev to IQVIA, and I watched entire categories of clinical trial technology emerge, mature, and get disrupted. I know what disruption looks like from the inside.
What's happening right now with AI is not a fad. The underlying technology is producing real, measurable results in real workflows, today.
Matt contends that most people are underestimating the pace of change. He's right that waiting to engage with AI until it feels “safe” or “proven” is a losing strategy. And he's right that the professionals who invest early will have a significant advantage.
I know this because I'm living it. It's why I have completed courses in agentic AI economics and building AI agents and am enrolled in Angela Radcliffe's AI Builder's Guild, building functional AI solutions for real business problems. I'm not dabbling. I'm investing seriously, because the disruption Matt describes is real.
Where Ann Resonates
Ann's counterpoint matters enormously — especially in my world.
She argues that Shumer's entire framework rests on one assumption: faster and cheaper always wins. And she's spot on that this skips several major steps of economic and social reality.
In clinical research and pharmaceutical procurement, those steps have names: regulatory compliance, patient safety, validated systems, audit trails, and legal liability. These are the structural foundations of an industry where the cost of getting it wrong isn't a bad quarter — it's a patient's life.
A health tech startup can build a brilliant AI-powered clinical trial platform. But when that startup walks into a meeting with a VP of Clinical Operations at a top-20 pharma company, the conversation won't be about speed. It will be about trust.
Can your system produce a validated audit trail that satisfies 21 CFR Part 11? How do you handle cross-border data transfers under GDPR? What happens to patient data if your startup folds? Can you survive a vendor qualification audit?
These aren't bureaucratic obstacles that AI will sweep away. They are the guardrails that protect patients in clinical trials. No amount of AI acceleration changes the fundamental requirement that someone with deep domain knowledge needs to guide the decisions that matter most.
There's More To It
What's flawed about this debate is that it presents experience and rapid AI fluency as conflicting forces. As if you must choose between being a seasoned expert who invests time to achieve value or an AI-savvy disruptor who works at light speed. As if the “dinosaurs” are on one side and the future is on the other.
That framing is incomplete in regulated industries.
Health tech founders don't need an advisor who simply understands the latest AI tools. What they need is someone who understands these tools AND who can tell them where the landmines are — someone who has sat across the table from pharma procurement teams and knows what they're actually evaluating. Someone who has seen what happens when a promising startup stumbles on a compliance gap they didn't know existed.
That knowledge comes from decades of doing the work. Exactly the kind of compounding experience Ann describes.
But that experience only retains its value if you're also keeping pace with how the landscape is shifting. A consultant who spent 20 years in clinical operations but has never seriously engaged with AI will increasingly struggle to advise founders building AI-native products. The founders will, quite rightly, question what that person can teach them about a world they don't understand.
This is the honest truth I think about constantly: experience without evolution becomes nostalgia. And innovation without experience becomes recklessness. Ann is right that we should not panic, but we must act with urgency to evolve in the ecosystem Matt has illustrated.
What Health Tech Founders Should Look For
If you're a health tech founder preparing to enter the biopharma market, this debate has direct implications for the guidance you seek.
Don't hire the advisor who dismisses AI and insists the old playbook still works. The procurement landscape is shifting. Pharma companies are beginning to evaluate AI capabilities as part of vendor assessments, and your advisor needs to be fluent in where the conversation is heading.
But also don't hire the advisor who only understands AI and lacks the regulatory and commercial context to apply it. They'll help you build a technically impressive product that gets rejected in the first vendor qualification round because nobody thought about GxP validation.
Look for the combination: deep domain expertise that has been deliberately, continuously upgraded. Someone who understands both why 21 CFR Part 11 matters AND how AI agents are beginning to reshape clinical data management. Someone with the scar tissue from navigating pharma procurement and the current fluency to help you position your AI-powered solution in language that procurement teams will trust.
That combination is rarer than you might think. And it's where the real value lives.
The Adaptive Master: Navigating the Future of Health Tech
In the dynamic landscape of health technology, the choice isn't between clinging to past expertise or blindly embracing every new innovation. True leadership emerges from the adaptive master—the expert who seamlessly integrates decades of hard-won judgment with a proactive, future-ready approach to emerging technologies like AI. This blend of deep domain knowledge and continuous evolution is not merely an advantage; it is the essential foundation for building trust, ensuring compliance, and driving meaningful progress in highly regulated environments.
For health tech founders, this means seeking guidance from those who understand both the intricate regulatory pathways and the transformative power of AI. It means partnering with advisors who possess the 'scar tissue' of navigating complex pharma procurement, coupled with the fluency to position AI-powered solutions in a language that resonates with industry leaders. This rare combination is where genuine value resides, enabling innovation that is both groundbreaking and responsibly implemented.
Ultimately, the future belongs not to the fastest or the most experienced in isolation, but to those who continuously earn trust by evolving their expertise.
